A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design.

Gregory W AlbersBruce C V Campbell Maarten G LansbergJoseph BroderickKen ButcherMichael T FroehlerLee H SchwammAmre M NouhDavid S LiebeskindFlorence ToyMing YangLori MassaroMegan SchoefflerBarbara Purdon

Published in: International journal of stroke : official journal of the International Stroke Society (2022)

Results from TIMELESS will contribute to understanding of the safety and efficacy of tenecteplase administered 4.5-24 h following symptom onset for patients with an ICA or MCA occlusion.

Keyphrases

double blind
phase iii
placebo controlled
clinical trial
open label
phase ii
end stage renal disease
study protocol
ejection fraction
high resolution
pulmonary embolism
newly diagnosed
patient reported
randomized controlled trial
peritoneal dialysis
fluorescence imaging